WT1 and glioblastoma: WT1 is a TAA highly overexpressed in GBM, while DSP-7888, a WT1 peptide vaccin e, has gone through a dose-escalation trial and been undergoing a phase III trial combined with BEV in patients with rGBM [120, 121].